Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers

Lancet. 2023 Mar 11;401(10379):796-798. doi: 10.1016/S0140-6736(22)02631-9. Epub 2023 Feb 9.

Authors

Ursula Maria Vogl¹, David McDermott², Thomas Powles³

Affiliations

¹ Oncology Institute of Southern Switzerland, Ente Ospedaliere Cantonale, Bellinzona, Switzerland.
² Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA.
³ Barts Cancer Centre, Queen Mary University of London, London EC1A 7BE, UK. Electronic address: thomas.powles1@nhs.net.

PMID: 36774931
DOI: 10.1016/S0140-6736(22)02631-9

No abstract available

Publication types

Comment

MeSH terms

Adjuvants, Immunologic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Renal Cell* / drug therapy
Humans
Ipilimumab
Kidney Neoplasms* / drug therapy
Nivolumab
Sunitinib / therapeutic use

Substances

Nivolumab
Ipilimumab
Sunitinib
Adjuvants, Immunologic